Core Viewpoint - The approval of the IND application for CS2009 by the FDA marks a significant advancement in the global development of this innovative immunotherapy for advanced solid tumors [1] Group 1: Company Developments - 基石药业's stock rose over 5% in early trading, currently at 6.19 HKD with a trading volume of 26.55 million HKD [1] - The company announced that its core asset CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, has received FDA approval for its Phase II clinical trial application [1] Group 2: Clinical Trial Insights - Preliminary data from the Phase I clinical study of CS2009 will be presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting, indicating good safety and tolerability, along with positive anti-tumor activity data [1] - Additional data from both Phase I and Phase II clinical studies is expected to be released at the upcoming American Society of Clinical Oncology (ASCO) and ESMO meetings this year [1]
港股异动 | 基石药业-B(02616)早盘涨超5% 旗下CS2009 II期临床试验申请获美国FDA批准